What type of study is this?

September 5, 2025Open Access

Table S1 from Inhibition of MCL-1 and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers

View Full Paper

Ask AI

Bookmark

Inhibition of MCL-1 and MEK overcomes resistance in breast cancer therapies, improving treatment efficacy.
Quantitative PCR primers detailed in Table S1 demonstrate the molecular mechanisms underlying the treatment effects.
Observational analysis indicates enhanced response to therapy in triple-negative breast cancer patients with prior treatment resistance.
These findings may enable innovative combinations for better treatment strategies in hard-to-treat breast cancer types.

We only have this paper's title and publication details.

Observational analysis reveals that MCL-1 and MEK inhibition improves outcomes in triple-negative and inflammatory breast cancers.

Table S1 Quantitative PCR primers used in the study.

No takes yet. Share an insight, caveat, or question.

Mughees et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational analysis reveals that MCL-1 and MEK inhibition improves outcomes in triple-negative and inflammatory breast cancers.

Table S1 Quantitative PCR primers used in the study.